

# HEART, DIABETES AND KIDNEY: MAKE THE LINK

15 – 17 December 2022, Cairo Marriott Hotel, Egypt

# PROGRAM

Education. Dedication. Care
www.onlinediabetes.net
Center for Diabetes Education

MOREHOUSE SCHOOL OF MEDICINE
*Office of Extended Professional Education*

onlinediabetes.net/cmr

# Accreditation Statement

**The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 16.0 AMA PRA Category 1 Credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity**

MOREHOUSE SCHOOL OF MEDICINE | *Office of Extended Professional Education*

## International Faculty


Guillermo Umpierrez


Robert Eckel


Stefano Delprato


Petar Seferovic


Antonio Ceriello


Yehuda Handelsman


Ania M. Jastreboff


Sam Klein


Carol H. Wysham


Jason Baker


Mahmoud Ibrahim


Francesco Cosentino


Abraham Thomas


Mohamed Eid


Eberhard Standl


Melanie J Davies


Peter Gaede


Oliver Schnell


Paolo Pozzilli


David Leslie


Per-Henrik Groop


Jaakko Tuomilehto


Paul Valensi


Peter Kurtzhals


Leo Seman


Luc Vaan Gaal

# Welcome Message

On behalf of the steering committee of the international conference on **"Heart, Diabetes, and Kidney – Make the Link"**, we have the pleasure of inviting you to participate in this unique educational event and associated scientific sessions. The first inaugural program will be held on 15-17 December 2022 in Cairo, Egypt which will mark the kickoff for a series of annual Scientific Sessions to take place on a longitudinal basis. More information can be found at www.onlinediabetes.net/CMR. This will be a 3-days international convention featuring the best of basic and clinical science as well as world-renowned faculty of speakers; all focused-on Cardio-Metabolic Renal diseases.

This conference is a timely reminder of the inter-related pathology of today's non-communicable chronic diseases in the setting of diabetes, metabolic, cardiovascular, and renal burden along with the complexity of their related disorders.

This conference is part of a coordinated global initiative aiming to address various aspects to advance knowledge, enhance care and accelerate the adoption of the latest guidelines in routine practice in the areas Cardio-Metabolic Renal diseases. In addition to our signature annual scientific session "Heart, Diabetes, and Kidney – Make the Link"; we are working on many relevant initiatives including but not limited to:

- Exploring opportunities to create a new subspecialty and certification program in cardio-metabolic-renal medicine.
- Drafting a curriculum for postgraduate courses, diplomas and Master degrees addressing this new subspecialty to be endorsed by different academic institutes.
- Have a well validated Cardio-Metabolic Renal risk score
- Developing a new algorithm to identify, diagnose, and treat these disorders collectively along with integrating the relevant local dynamics and concerns into viable clinical care roadmaps.
- Encourage research projects in these domains and offer training and workshops.
- Supporting international and regional educational initiatives on cardio-metabolic-renal topics.

**looking forward to welcoming you!**



**Eberhard Standl, MD**
***Retired chairman, Forschergruppe Diabetes e.V. at Munich Helmholtz Centre***




**Mahmoud Ibrahim, MD**
***Director, EDC Center for Diabetes Education, Charlotte, NC, USA***

# DAY1 | THURSDAY | DECEMBER 15TH

| | |
|---|---|
| 8:00 – 9:00 | Registration |
| 9:00 – 9:15 | Welcome Remarks |

Meeting Room (AIDA 3-4)

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 09:15 – 10:30 AM | **SESSION 1**<br>**Symposium, European Study Group "Diabetes & CVD"**<br>**Theme:** Heart Failure in Diabetes and Renal Disease<br>D&CVD<br>**CHAIRPERSONS** | |
| | Eberhard Standl, *Germany* | Antonio Ceriello, *Italy* |
| | "Heart Failure in Diabetes and Renal Disease – Making the Link"<br>-Perspectives of the cardiologist | Petar Seferovic, *Serbia* |
| | "Heart Failure in Diabetes and Renal Disease – Making the Link"<br>-Perspectives of the nephrologist | Per-Henrik Groop, *Finland* |
| | "Heart Failure in Diabetes and Renal Disease – Making the Link"<br>-Perspectives of the diabetologists | Paul Valensi, *France* |



Meeting Room (AIDA 3-4)

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 10:30 - 11:30 AM | **SESSION 2**<br>**Symposium, Barts Hospital University of London and University of Rome**<br>**Theme:** Diabetes Complications: are genes irrelevant? | |
| | **CHAIRPERSONS** | David Leslie, *UK*<br>Amal Rizk, *Egypt*<br>Paolo Pozzilli, *Italy* |
| | Heart | Abraham Thomas, *USA* |
| | Renal | Per-Henrik Groop, *Finland* |
| | Diabetes on both | David Leslie, *UK* |
| | 11:30-12:00 pm Break (visit the exhibit) | |

## SESSION 3 DEBATE SESSIONS

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 12:00 - 12:30 | **Debate I** Metformin is still the main foundation in treating Type 2 Diabetes | |
| | **CHAIRPERSONS** | Eberhard Standl, *Germany*<br>Fathi Makladi, *Egypt* |
| | No | Peter Gaede, *Denmark* |
| | Yes | Mahmoud Ibrahim, *USA* |

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 12:30-13:00 | **Debate II** Lipid management, what after statin? | |
| | **CHAIRPERSONS** | Mohamed Sobhy, *Egypt*<br>Hala Mahfouz, *Egypt* |
| | Ezetimibe ± bempedoic acid | Robert Eckel, *USA* |
| | PCSK9 (Inclisiran) | Yehuda Handelsman, *USA* |

Meeting Room (AIDA 3-4)

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 13:00-13:30 | **Debate III** The big four in Heart Failure treatment<br>**CHAIRPERSON**<br>Aly Kasem, *Egypt* Magdy Abdelhamid, *Egypt* | |
| | Simultaneous | Petar Seferovic, *Serbia* |
| | Sequential | Paul Valensi, *France* |

## SESSION 4

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 13:30 – 14:30 | OBESITY<br>**CHAIRPERSON**<br>Gamela Nasr, *Egypt* Ahmed Magdy, *Egypt* | |
| | Weight loss or glycemic control, which comes first? | Samuel Klein, *USA* |
| | NAFLD: major challenge against cardiometabolic health | Megahed Abu Al Magd, *Egypt* |
| | Evaluating incretin co-agonists | Melanie Davies, *UK* |
| | Obesity in the Arab countries compared to the US | Ebtesam Ba-Essa, *KSA*<br>Mahmoud Ibrahim, *USA* |
| | Role of Bariatric Surgery | Abraham Thomas, *USA* |

14:30 Lunch Break (product theatre, Boehringer Ingelheim)

# DAY2 | FRIDAY | DECEMBER 16TH

| | |
|---|---|
| 9:00 -10:00 | Registration |

Meeting Room (AIDA 3-4)

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 10:00 -11:30 | **SESSION 5**<br>CVOTs UPDATES DECEMBER 2022<br>**CHAIRPERSON**<br>Eberhard Standl, *Germany* Bassem Zarif, *Egypt* | |
| | CVOTs Session I<br>"Trial Update on mineralocorticoid receptor antagonists in reducing cardio-renal disease" | Oliver Schnell, *Germany* |
| | CVOTs Session II<br>"Trial Update on SGLT2-inhibitors in reducing cardio-renal disease", | Paul Valensi, *France* |
| | CVOTs Session III<br>"Trial Update on GLP-1 RAs in reducing cardio-renal disease" | Peter Gaede, *Denmark* |
| 11:30 – 13:00 Break (visit the exhibit - prayer) | | |

Meeting Room (AIDA 3-4)

**SESSION 6** STATE OF THE ART LECTURE

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 13:00 – 13:20 | **CHAIRPERSON**<br>Paul Valensi, *France* Ahmed Tag Eldin *Egypt* | |
| | New DCRM Multi Specialty recommendations | Yehuda Handelsman, *USA* |
| 13:20 – 13:30 Break - visit the exhibit | | |

Meeting Room (AIDA 3-4)

## SESSION 7

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 13:30 – 15:00 | Established Learnings from CVOTs | |
| | **CHAIRPERSONS** | |
| | | Adel Aletrby *Egypt* — Jaakko Tuomilehto, *Finland* |
| | From glucose-lowering agents to disease/ diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes". | Stefano Del Prato, *Italy* |
| | "Multifactorial CV risk management in diabetes: the Steno 2 trial trajectory". | Peter Gaede, *Denmark* |
| | "Glycemic management in diabetes: old and new approaches". | Antonio Ceriello, *Italy* |
| | "Role of insulin and/or severe hypoglycemia in the context of the cardio-centric approach". | Eberhard Standl, *Germany* |
| 15:00 -16:30 | EDC Session (Refreshment will be served) | |
| 17:00 – 19.00 | Dinner Corporate (non-CME) Symposium Boehringer Ingelheim | |



# DAY3 | SATURDAY | DECEMBER 17TH

| | |
|---|---|
| 8:00 – 9:00 | Registration |

Meeting Room (AIDA 3-4)

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 9:30 - 10:30 | **SESSION 8**<br>Professional organizations guidelines<br>**CHAIRPERSONS**<br>Robert Eckel, *USA* — Magdy El-Sharkawy, *Egypt* | |
| | ADA Standards of Medical Care in Diabetes 2023 | Guillermo Umpierez, *USA* |
| | ESC & EASD Updates of Diabetes Guidelines: | Francesco Cosentino, *Sweden* |
| | AACE | Guillermo Umpierez, *USA* |
| | ESC Heart Failure Guideline 2021 | Petar Seferovic, *Serbia* |
| | KDIGO Diabetes Management in CKD Guideline: | Per-Henrik Groop, *Finland* |
| | Misdiagnosis of the type of diabetes in the application of guidelines for therapy | Paolo Pozzilli, *Italy* |

Meeting Room (AIDA 3-4)

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 10:30 – 11:30 | **SESSION 9**<br>Cardio-Metabolic Renal diseases among special populations<br>**CHAIRPERSON**<br>Mahmoud Ibrahim, *USA* | |
| | Women | Carol Wysham, *USA* |
| | Athletes | Peter Gaede, *Denmark* |
| | African Americans | Abraham Thomas, *USA* |

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 10:30 – 11:30 | **SESSION 10** *Hall B (AIDA 2)*<br>LIPIDS<br>CHAIRPERSON<br>*Ahmed Elbarbary, Egypt* | |
| | Hypertriglyceridemia | Paul Valensi, *France* |
| | What is beyond LDL lowering | Robert Eckel, *USA* |
| | Omega-3 Debate | Jaakko Tuomilehto, *Finland* |
| | ICOSAPENT ETHYL | Yehuda Handelsman, *USA* |
| | 11:30 – 12:00 Coffee Break (visit the exhibit) | |

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 12:00 – 13:15 | **SESSION 11** *Hall A (AIDA 3-4)*<br>Symposium : World Community for Prevention of Diabetes WCPD<br>Cardiometabolic Prevention<br>WCPD<br>CHAIRPERSONS<br>Jaakko Tuomilehto, *Finland* — Mahmoud Ibrahim, *USA* | |
| | Early prevention of diabetic neuropathy with lifestyle intervention and antidiabetic drugs in people with prediabetes | Rafael Gabriel, *Spain* |
| | The role of Epigenetics, | Francesco Cosentino, *Sweden* |
| | Heart Failure and its Prevention, the pharmacist's roles | Magdy Abdel Hamid *Egypt* |
| | How to develop a validated CVD risk score? | Jaakko Tuomilehto, *Finland* |


| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 12:00 – 13:15 | **SESSION 12** *Hall B (AIDA 2)*<br>TECHNOLOGY<br>CHAIRPERSON<br>Robert Eckel, *USA* Fady Azmy, *Egypt* | |
| | CGM & Pumps | Jason Baker, *USA* |
| | Time in Range and Cardiometabolic risks | Oliver Schnell, *Germany* |
| | Type 1 Diabetes: Current state of art therapy, | Jason Baker, *USA* |

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 13:15 – 14:30 | **SESSION 13** *Hall A (AIDA 3-4)*<br>Nutrition Session<br>CHAIRPERSON<br>Megahed Abu Almagd, *Egypt* | |
| | Review of the dietary guidelines | Jaakko Tuomilehto, *Finland* |
| | Mediterranean diet | Rafael Gabriel, *Spain* |
| | Efficacy and Safety of VLCD, KETO Diets and intermittent fasting | Luc Van Gaal, *Belgium* |
| | Carb counting | Safaa Tawfik, *Egypt* |

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 13:15 – 14:30 | **SESSION 14** *Hall B (AIDA 2)*<br>Emerging options to tackle Obesity in the context of Diabetes | |
| | **CHAIRPERSON** | |
| | Paul Valensi, *France* | |
| | Obesity and its complications: No Single Specialty escapes | Luc Van Gaal, *Belgium* |
| | Most updated clinical trials addressing obesity | Jaakko Tuomilehto, *Finland* |
| | Tirzepatide for obesity treatment | Ania M. Jastreboff, *USA* |
| | Childhood Obesity | Jason Baker, *USA* |

| TIME | SESSION/LECTURE | FACULTY |
|---|---|---|
| 14:30 - 15:00 | **SESSION 15** *Hall A (AIDA 3-4)*<br>A look at the Future - What's in the Pipeline? | |
| | **CHAIRPERSON** | |
| | Yehuda Handelsman, *USA* | |
| | Boehringer Ingelheim | Leo Seman, *USA* |
| | Novo Nordisk | Peter Kurtzhals, *Denmark* |

**15:00 Lunch , Adjourn**



## Global Summit

**Aim: to issue a Global Statement titled:**
**Cardio-Metabolic Renal Medicine in Primary Care Setting**
**Cairo Marriott Hotel**

### Chairs:

- Mahmoud Ibrahim, USA
- Eberhard Standl, Germany

### Members (Potential Authors):

- Guillermo Umpiérrez, USA
- Robert Eckel, USA
- Yehuda Handelsman, USA
- Melanie Davies, UK
- Stefano Del-Prato, Italy
- Ania M. Jastreboff USA
- Jason Baker, USA
- Samuel Klein, USA
- Petar Sefervic, Serbia
- Luc Vaan Gaal Belgium
- Peter Gaede, Denmark
- Abraham Thomas, USA
- Francesco Cosentino, Sweden
- Paul Valensi, France
- Jaakko Tuomilehto, Finland
- Pam Taub, USA
- Oliver Schnell, Germany
- Paolo Pozzilli, Italy
- David Leslie, UK

Heart, Diabetes, and Kidney – Make the Link

# Insulin Leaders Program

**December 15th, 2022**
**9:00 AM – 2:00 PM** (AIDA 1)

## Program Overview

Insulin therapy for either Type 1 or Type 2 Diabetes continues to evolve and expand. This new Insulin Leaders Program should include a comprehensive of the types of insulin available currently and in the near future along with an ample discussion of the different treatment protocols for the use of insulin based on the most updated ADA/EASD Consensus.

## Program Objcetives

At the end of this program, participants will be able to:

- List the goals of insulin therapy and the updated treatment goals including A1C & Time in Range TIR
- Compare and discuss the types and concentrations of the available insulin
- Describe the barriers to insulin therapy and the strategies to overcome
- Recognize the roles of Technology in the insulin use including the CGM , Pump and Time in Range TIR
- Define when insulin should be used in type 2 Diabetes
- List the latest in the insulin delivery including the weekly insulin
- Define the communications and teaching skills to be an Insulin Leader

# Accreditation Statement

The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 6.0 AMA PRA Category 1 Credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity

The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 6.0 AMA PRA Category 1 Credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity

MOREHOUSE SCHOOL OF MEDICINE | *Office of Extended Professional Education*



## Faculty



**Guillermo Umpiérrez, USA**
*President of the American Diabetes Association, Medicine and Science*



**Robert Eckel, USA**
*Immediate Past President of the American Diabetes Association, Medicine and Science*

## Accreditation

The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 6.0 AMA PRA Category 1 Credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity

MOREHOUSE SCHOOL OF MEDICINE | *Office of Extended Professional Education*



# Agenda

9:00 – 10:00
## Session 1
- ADA/EASD Consensus and Glycemic Targets
- Insulin in type 2 Diabetes
- Insulin replacement rules : Basal and Meal related

10:00 – 11:30
## Session 2
- Insulin in Type 1 Diabetes
- Insulin in pregnancy
- Insulin use inside the hospital
- Pump therapy

11:30 – 12:00
## Break

12:00 – 13:00
## Session 3
- Patient Education
- Insulin in Cardio-Renal Diseases
- Insulin use in the elderly

13:00 – 14:00
## Session 4
- Monitoring of Glycemic control , the role of CGM
- Time in Range TIR
- Hypoglycemia
- Patient Education
- Case Study
- Communications and Teaching skills

14.00
## Lunch

Heart, Diabetes, and Kidney – Make the Link

# Heart Failure Leaders Program

**December 15th, 2022**
**9.00 AM – 2.00 PM** *(AIDA 2)*

## Program Overview

Heart failure (HF) prevalence is on the rise worldwide, even though its burden is expected to spike especially with the expected increase in the prevalence of diabetes as a major and independent risk factor for HF. According to a statement published this year in Diabetes Care, patients with diabetes could experience a ~3.0-fold increase in HHF risk and a ~1.5-fold increase in mortality from HF . The recent use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), proved to consistently reduce HHF risk by 32%, this may raise the hope for improvement of the outcome. Yet, this epidemiological picture may warrant the need for educational and training programs aiming to increase awareness of this problem in the Primary Care setting.

## Program Objectives

At the end of this program, participants will be able to:

- List the ways of early detection of Heart Failure, especially among people with Diabetes
- Compare and discuss the types of Heart Failure
- Describe the traditional and new therapies for Heart Failure
- Recognize the roles of Technology in the diagnosis of Heart Failure
- List the latest in the CVOTs and the Heart Failure outcomes
- Define the communications and teaching skills to be an Insulin Leader

## Accreditation

The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 6.0 AMA PRA Category 1 Credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity

MOREHOUSE SCHOOL OF MEDICINE | *Office of Extended Professional Education*

## Faculty



### Petar Seferovic, Serbia

*Past President of the Heart Failure Association (HFA), ESC*
*Vice President of the European Society of Cardiology(ESC)*
*Professor, Belgrade University School of Medicine*
*President, Heart Failure Society of Serbia*



### Magdy Abdelhamid, Egypt

*Professor & Chairman of the Cardiology Department, Faculty of Medicine, Cairo University, Egypt*
*Board Member of the Heart Failure Association (HFA), ESC (2020-2022)*
*Co-Chair of the Educational Committee of HFA, ESC (2022-2024)*
*Member of the Committee for Practice Guidelines, ESC (2020-2022)*
*Past President, Egyptian Society of Cardiology*
*President, Egyptian Working Group of Heart Failure*
*Board member of the Egyptian Society of Cardiology*

# Agenda

9:00 – 10:30 am

## Session 1 Epidemiology and Diagnosis

- Epidemiology and magnitude of the problem
- Universal definition of heart failure
- Biomarkers in heart failure
- Prevention of heart failure

10:30 – 11:30 am

## Session 2 Management

- HF Guidelines (European 2021& American 2022)
- Patient profile and tailoring therapy in HF
- Device therapy in HF

11:30 – 12:00

## Break

12:00 – 13:45

## Session 3 Management (cont.)

- HFpEF updates in 2022
- Co-morbidities in HF
- SGLT2i, new era?
- Set-up of dedicated HF clinic
- Case Study

Heart, Diabetes, and Kidney – Make the Link

# Lipid Clinic Program

**December 16th, 2022**

**9.00 AM – 12.00 PM** *(Meeting Room - AIDA 1)*

## Program Overview

Dyslipidemia which is characterized by abnormal cholesterol and triglyceride levelsis very common. It is linked to the heart disease being the No. 1 killer in the U.S and many countries. The current research shows that high low-density lipoprotein, or LDL cholesterol, and low high-density lipoprotein, or HDL cholesterol, increase the risk for heart attack, stroke and other cardiovascular diseases. improving cholesterol levels may not only slow the process of plaque buildup, but also reverse it in some instances. There is a crucial need for screening for abnormal lipid values, counseling on risk factors, including high cholesterol, high blood pressure, diabetes, smoking, being overweight, living a sedentary lifestyle, and family history. The above may warant the need for having specialized lipid clinics, educational and training programs aiming to increase the awareness of this problem .

## Program Objectives

At the end of this program, participants will be able to:

- Learn the Epidemiology and Pathophysiology of dyslipidaemia
- List the risk factors for ASCVD, the risk categories and assesment
- Discuss screening for ASCVD – timing , screening tests- Lipid panel, Lp (a), Advanced lipid testing, imaging- CAC
- Describe the lipid treatment goals and the guidelines
- List the medications for lipid disorders : a.LDL focused b. TGL focused
- Describe Women- special considerations
- Define the tools for treatment monitoring

Suggested Lipid Clinic Tasks:

- Screening for abnormal lipid values using a blood test.
- Explanation of lipid profile results.
- Counseling on risk factors, including high cholesterol, high blood pressure, diabetes, smoking, being overweight, living a sedentary lifestyle, and family history.
- Risk factor modification and referral to resources and programs at Mayo Clinic Health System, including smoking cessation, as well as exercise, weight-loss, diet and diabetes education.
- Medication management.

## Accreditation

The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 6.0 AMA PRA Category 1 Credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity

MOREHOUSE SCHOOL OF MEDICINE | *Office of Extended Professional Education*

# Faculty



Prof. Yehuda Handelsman USA

*Medical Director & Principal Investigator, Metabolic Institute of America*
*President Diabetes, CardioRenal & Metabolism Institute (DCMi)*



Prof. Gamela Nasr Egypt

*Professor and head of Cardiology Department at the Faculty of Medicine, Suez Canal University*
*Chair of the Preventive Cardiology and cardiac rehabilitation working group of the Egyptian Society of cardiology and Africa Representative of the International society of cardiovascular disease prevention*

# Agenda

**8:00 – 9:00 , Welcome and Breakfast**

**9:15 – 10:30**

## Session 1

- Global Epidemiology of ASCVD – Focus on Egypt, the Middle East.
- LDL Impact on ASCVD, the Lower the Better ( how low ? )
- Contemporary Lipids Guidelines: ACC, AACE, ESC, DCRM-Egypt
- Assessing Risk- screening tests, biomarkers, imaging Risk calculators
- Lipids Medications LDL Focused; dosage, combinations outcome

**10:30 – 12:00**

## Session 2

- Lipid Management in Hospitalized patients with Acute MI
- TGL management impact on ASCVD, the role of Icosapent Ethyl (IPE) & Inclisiran
- Lipid Clinic Structure and What's offered through the clinic?

Break will ongoing
Lunch will be served after



Diamond Sponsor

Boehringer Ingelheim

Thanks to Our Partners

novo nordisk®


NOVARTIS

SERVIER

EVA PHARMA
SECURING YOUR HEALTH

Glyxambi®
(empagliflozin/linagliptin) tablets
10 mg/5 mg, 25 mg/5 mg

# MAX POWER PROTECTION SAFETY [1-5]



EM-EG-100159


**References:**
1-Lewin A et al. Diabetes Care 2015;38:394.
2-DeFronzo RA et al. Diabetes Care 2015;38:384.
3-Søfteland E et al. Diabetes Care 2017;40:201.
4-Zinman B et al. N Engl J Med 2015;373:2117.
5-Rosenstock J et al. JAMA. 2019;321(1):69-7.



Boehringer Ingelheim

Boehringer Ingelheim Scientific Office - Egypt
Plot No. 15, First Sector, City Centre,
the Southern 90 Street, Fifth Settlement,
Postal code 11835
New Cairo, Egypt
Email Address: PV_local_Egypt@boehringer-ingelheim.com
24hr contact number: +2 (012) 7066 7262

For Healthcare Professionals Only

Jardiance®
(empagliflozin)
Film coated tablets

## JARDIANCE—NOW also APPROVED for HFpEF[1,2]

# IMPACT HEART FAILURE†

## JARDIANCE Clinically Proven* to reduce the risk of CV death or HHF in both HFrEF & HFpEF[3,4]



*Proven=meeting the primary endpoint in clinical trials.
†JARDIANCE 10 mg is indicated in adults for the treatment of symptomatic chronic heart failure.[‡2]


**REFERENCES:**
1. JARDIANCE [summary of product characteristics]. Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.Europa.eu. June 2021.
2. Egyptian drug authority empagliflozin approved insert leaflet 6/4/2022
3. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication's Supplementary Appendix.)
4. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR Preserved results and the publication's Supplementary Appendix.)


Boehringer Ingelheim


**Boehringer Ingelheim Scientific Office -Egypt**
Plot No. 15, First Sector, City Centre, the Southern 90 Street, Fifth Settlement, Postal code 11835 New Cairo, Egypt
Email Address: PV_local_Egypt@boehringer-ingelheim.com
24hr contact number: +2 (012) 7066 7262



PC-EG-101074



# HEART, DIABETES AND KIDNEY: MAKE THE LINK WAVE II

8 -10 DECEMBER 2023

ISTANBUL

WWW.ONLINEDIABETES.NET/CMR

*ACTIVE FROM JANUARY 15, 2023*

**PROGRAM COORDINATORS**

Hyam R.Tantawi, PhD

Heba Allah R.Tantawi, MD

PURE SPOT EVENTS MANAGEMENT


**PROJECT MANAGER**

Mr. Ahmed Elshabrawy (+2) 01000 978 239 - +1 704 666 2452 ahmed.elshabrawy@egypure.org

pure.spot www.purespot.org info@egypure.org